GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: IMP-4297 | IMP4297 | Paishuning® (China)
                                 
                                                         
                            
                            
                            
                                 
                                
                                senaparib is an approved drug 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Senaparib (IMP4297) is an oral poly(ADP-ribose) polymerase 1 (PARP1) inhibitor [1] that is being developed in a joint venture between IMPACT Therapeutics and Junshi Biosciences, for the treatment of BRCA-mutated solid tumours. It is one of the chemical structures claimed in patent WO2012130166A1 [2].
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| Senaparib potently kills tumour cells with BRCA1/2 mutations in vitro, and it is efficacious in BRCA1/2 mutant tumour xenograft models [1]. |